Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xynomic Pharmaceuticals Holdings Inc.

xynomicpharma.com

Latest From Xynomic Pharmaceuticals Holdings Inc.

Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor

US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.

Commercial Companies

Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began

But Q4 was the third sequential quarter with a decrease in financing totals. A review of biopharma start-up dealmaking and financing activity from October through December 2017, based on data from Strategic Transactions.

StartUps and SMEs Financing

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.

Deals Business Strategies

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Xynomic Pharmaceuticals Holdings Inc.
  • Senior Management
  • Mark Xu, Pres. & CEO
    Jason Wu, PhD, COO
  • Contact Info
  • Xynomic Pharmaceuticals Holdings Inc.
    1910 Thomes Ave.
    Cheyenne, WI 82001
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register